Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference

EMERYVILLE, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2015 Needham Healthcare Conference in New York on Tuesday, April 14, 2015 at 10:00 AM Eastern Standard Time.

The presentation will be webcast live and available for replay from the Adamas website at http://ir.adamaspharma.com/events.cfm in the Investor Relations section until May 14, 2015.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication associated with the treatment of Parkinson's disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company's portfolio also includes two approved products with Forest Laboratories Holdings Limited (a subsidiary of Actavis plc), Namzaric™ and Namenda XR®. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.

Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

Namzaric™ is a trademark of Actavis, Inc. or its affiliates.  

CONTACT: Susan Lehner
         Investor Relations & Corporate Communications
         Adamas Pharmaceuticals, Inc.
         Phone: 510-450-3567

You May Also Be Interested In

• Lightweight Inflatable Rooftop Tent Portal Nomis One Debuts on Kickstarter
• BNB Price Prediction Eyes $800 While AlphaPepe Turns Meme-Coin Demand Into a Live-Product Presale
• Hyundai Motor Group Executive Chair Euisun Chung Announces Physical AI Vision at San Francisco AI Summit